ACT vs BIIB · P/E 9.3, rev $629.4M vs P/E 21, rev $9.89B
Enact Holdings Inc (ACT) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Enact Holdings Inc (ACT) is a insurance - specialty company listed on NASDAQ.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Latest reported ACT revenue for 2026-06-30 was $629.4M. ACT currently screens at market cap $5.99B and trailing P/E 9.3.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
ACT currently screens at market cap $5.99B and trailing P/E 9.3. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the ACT and BIIB stock pages for the full models.
Not investment advice.